がん性悪液質の市場規模、シェア、成長分析：製品タイプ別、作用機序別、流通チャネル別、地域別 - 産業予測 2025年～2032年

がん性悪液質の世界市場規模は、2023年に28億3,000万米ドルと評価され、2024年の29億6,000万米ドルから2032年には42億1,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは4.5％で成長する見通しです。

National Center for Biotechnology Informationの最近のデータによると、悪液質は進行がん患者の約80％に影響を及ぼし、世界のがん関連死の20％に寄与しています。著しい体重減少、食欲不振、骨粗鬆症、貧血を特徴とするこの消耗症候群は、がん、COPD、HIVなどの慢性疾患で蔓延しており、米国では年間約130万人のがん患者に影響を及ぼしています。高齢化社会は特にがんに罹患しやすいため、がん性悪液質を標的とした治療法の開発には大きな市場開拓の機会があります。患者数の増加は、革新的な介入の必要性を強調し、市場拡大をさらに推進し、がん領域における重要な患者ケアの課題に対処します。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• ケーススタディ
• 規制情勢
• 特許分析

がん性悪液質市場規模：製品タイプ別& CAGR（2025-2032）

• 市場概要
• プロゲストーゲン
• コルチコステロイド
• 併用療法
• その他

がん性悪液質市場規模：作用機序別& CAGR（2025-2032）

• 市場概要
• 食欲増進剤
• 減量安定剤

がん性悪液質市場規模：流通チャネル別& CAGR（2025-2032）

• 市場概要
• 病院薬局
• 小売薬局
• オンライン薬局

がん性悪液質市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Merck & Co., Inc.（USA）
• Aphios Corporation（USA）
• Helsinn Group（Switzerland）
• Bristol-Myers Squibb Company（USA）
• Pfizer Inc.（USA）
• Eli Lilly and Company（USA）
• Novartis AG（Switzerland）
• Veru Inc.（USA）
• Mylan N.V.（USA）
• Hikma Pharmaceuticals PLC（UK）
• AbbVie Inc.（USA）
• Amgen Inc.（USA）
• AstraZeneca PLC（UK）
• Johnson & Johnson（USA）
• GlaxoSmithKline PLC（UK）
• F. Hoffmann-La Roche AG（Switzerland）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Takeda Pharmaceutical Company Limited（Japan）

結論と推奨事項

Global Cancer Cachexia Market size was valued at USD 2.83 billion in 2023 and is poised to grow from USD 2.96 billion in 2024 to USD 4.21 billion by 2032, growing at a CAGR of 4.5% during the forecast period (2025-2032).

Recent data from the National Center for Biotechnology Information indicates that cachexia affects around 80% of advanced cancer patients, contributing to 20% of cancer-related deaths worldwide. This wasting syndrome, characterized by significant weight loss, anorexia, osteoporosis, and anemia, is prevalent in chronic diseases like cancer, COPD, and HIV, impacting approximately 1.3 million cancer patients annually in the U.S. As the global cancer incidence continues to rise, so does the potential market for cachexia treatments. With the aging population particularly vulnerable to cancer, there is substantial market opportunity for developing therapies targeting cancer cachexia. The growing patient population emphasizes the need for innovative interventions, further propelling market expansion and addressing critical patient care challenges in the oncology space.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Cachexia market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Cachexia Market Segments Analysis

Global Cancer Cachexia Market is segmented by Product Type, Mechanism of Action, Distribution Channel and Region. Based on Product Type, the market is segmented into Progestogens, Corticosteroids, Combination Therapies and Others. Based on Mechanism of Action, the market is segmented into Appetite Stimulators and Weight Loss Stabilizers. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cancer Cachexia Market

The global Cancer Cachexia market is primarily driven by the limited treatment options currently available for managing cachexia in cancer patients, which predominantly include progestogens and corticosteroids. While these medications have demonstrated some effectiveness, the variability in clinical outcomes highlights a significant unmet need, as there are no specific drug approvals tailored for this condition. This gap in therapeutic solutions presents an opportunity for market participants to engage in research and development efforts aimed at creating innovative treatments. As companies strive to address this deficiency, the global market is poised for growth through the introduction of novel drug candidates.

Restraints in the Global Cancer Cachexia Market

Although the global cancer cachexia market is witnessing a rise in prevalence, several challenges are hindering its expansion. These include the exorbitant costs linked to cancer and its adjunct treatments, along with inadequate drug reimbursement in developing nations. Treatment expenses for cancer patients suffering from cachexia are generally higher than those for non-cachexia patients, resulting in significant out-of-pocket expenses. Additionally, the scarcity of approved therapeutic options for this condition further hampers market growth. Consequently, these factors are likely to lead to a gradual increase in the market throughout the projected timeframe.

Market Trends of the Global Cancer Cachexia Market

The global cancer cachexia market is witnessing a notable trend towards the adoption of combination therapies, driven by the limitations of traditional single-drug approaches, which often yield insufficient therapeutic benefits. With a scarcity of approved drugs specifically for cancer cachexia, healthcare providers are increasingly embracing multicomponent strategies that integrate both pharmacological and non-pharmacological interventions. Clinical trials have demonstrated significant improvements in lean body mass (LBM) among patients receiving these combination therapies. As healthcare professionals advocate for these multifaceted treatment regimens, patient acceptance is rising, thereby fueling demand and expanding opportunities in the global cancer cachexia market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Patent Analysis

Global Cancer Cachexia Market Size by Product Type & CAGR (2025-2032)

• Market Overview
• Progestogens
• Corticosteroids
• Combination Therapies
• Others

Global Cancer Cachexia Market Size by Mechanism of Action & CAGR (2025-2032)

• Market Overview
• Appetite Stimulators
• Weight Loss Stabilizers

Global Cancer Cachexia Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Global Cancer Cachexia Market Size & CAGR (2025-2032)

• North America (Product Type, Mechanism of Action, Distribution Channel)
  • US
  • Canada
• Europe (Product Type, Mechanism of Action, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Mechanism of Action, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Mechanism of Action, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Mechanism of Action, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aphios Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Helsinn Group (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Veru Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations